Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05288166
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:39.209444+00:00
Published At
2025-06-27T00:00:00+00:00
Record Updated At
2025-06-27
Results Posted At
2025-06-27
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Prostatic Neoplasms", "Neoplasm Metastasis", "Urogenital Neoplasms", "Physiological Effects of Drugs", "Antineoplastic Agents", "Antineoplastic Agents, Hormonal", "Androgens", "Hormones", "Hormones, Hormone Substitutes, and Hormone Antagonists", "Abiraterone Acetate", "Steroid Synthesis Inhibitors", "Cytochrome P-450", "Enzyme Inhibitors", "Prednisone", "Prednisolone", "Cyclin-Dependent Kinase 4", "Cyclin-Dependent Kinase 6"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-06-27"
protocolSection.identificationModule.nctId
"NCT05288166"
protocolSection.identificationModule.officialTitle
"CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2025-06-27"

Study condition terms

  • Prostatic Neoplasms (protocolSection.conditionsModule.conditions)
  • Neoplasm Metastasis (protocolSection.conditionsModule.conditions)
  • Urogenital Neoplasms (protocolSection.conditionsModule.conditions)
  • Physiological Effects of Drugs (protocolSection.conditionsModule.conditions)
  • Antineoplastic Agents (protocolSection.conditionsModule.conditions)
  • Antineoplastic Agents, Hormonal (protocolSection.conditionsModule.conditions)
  • Androgens (protocolSection.conditionsModule.conditions)
  • Hormones (protocolSection.conditionsModule.conditions)
  • Hormones, Hormone Substitutes, and Hormone Antagonists (protocolSection.conditionsModule.conditions)
  • Abiraterone Acetate (protocolSection.conditionsModule.conditions)
  • Steroid Synthesis Inhibitors (protocolSection.conditionsModule.conditions)
  • Cytochrome P-450 (protocolSection.conditionsModule.conditions)
  • Enzyme Inhibitors (protocolSection.conditionsModule.conditions)
  • Prednisone (protocolSection.conditionsModule.conditions)
  • Prednisolone (protocolSection.conditionsModule.conditions)
  • Cyclin-Dependent Kinase 4 (protocolSection.conditionsModule.conditions)
  • Cyclin-Dependent Kinase 6 (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.